Shares of agilon health, inc. (NYSE:AGL – Get Rating) have earned an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $28.38.
Several research analysts have recently commented on the company. Wells Fargo & Company decreased their target price on agilon health from $28.00 to $22.00 and set an "overweight" rating for the company in a research report on Tuesday, November 15th. Stifel Nicolaus assumed coverage on shares of agilon health in a report on Thursday, December 8th. They issued a "buy" rating and a $23.00 price objective for the company. SVB Leerink lowered their target price on shares of agilon health from $33.00 to $30.00 and set an "outperform" rating for the company in a research note on Friday, November 4th. Finally, The Goldman Sachs Group reduced their price target on shares of agilon health from $38.00 to $34.00 and set a "buy" rating on the stock in a research report on Tuesday, November 15th.
Get agilon health alerts:Insider Buying and Selling at agilon health
In other agilon health news, insider Benjamin Kornitzer sold 5,396 shares of the firm's stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $19.92, for a total value of $107,488.32. Following the sale, the insider now owns 10,426 shares in the company, valued at $207,685.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other agilon health news, insider Benjamin Kornitzer sold 5,396 shares of the business's stock in a transaction on Friday, January 20th. The stock was sold at an average price of $19.92, for a total transaction of $107,488.32. Following the completion of the transaction, the insider now owns 10,426 shares in the company, valued at approximately $207,685.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Benjamin Shaker sold 20,723 shares of the firm's stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $19.78, for a total value of $409,900.94. Following the transaction, the insider now directly owns 25,625 shares in the company, valued at $506,862.50. The disclosure for this sale can be found here. Insiders sold 39,613 shares of company stock valued at $746,114 in the last ninety days. Company insiders own 3.30% of the company's stock.
Institutional Trading of agilon health
Hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its holdings in shares of agilon health by 14.9% in the second quarter. FMR LLC now owns 34,862,287 shares of the company's stock valued at $761,043,000 after acquiring an additional 4,512,008 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of agilon health by 14.7% in the third quarter. Vanguard Group Inc. now owns 18,770,560 shares of the company's stock valued at $439,605,000 after buying an additional 2,407,116 shares during the period. Wellington Management Group LLP boosted its stake in agilon health by 11.0% during the first quarter. Wellington Management Group LLP now owns 18,578,035 shares of the company's stock valued at $470,953,000 after buying an additional 1,834,890 shares in the last quarter. Capital Research Global Investors grew its holdings in agilon health by 18.4% during the first quarter. Capital Research Global Investors now owns 9,867,875 shares of the company's stock worth $250,151,000 after acquiring an additional 1,536,506 shares during the period. Finally, Durable Capital Partners LP raised its position in agilon health by 34.0% in the third quarter. Durable Capital Partners LP now owns 9,429,055 shares of the company's stock worth $220,828,000 after acquiring an additional 2,392,134 shares in the last quarter.agilon health Trading Up 5.6 %
NYSE AGL opened at $21.76 on Wednesday. The company's fifty day moving average price is $17.83 and its two-hundred day moving average price is $20.64. The company has a market capitalization of $8.96 billion, a price-to-earnings ratio of -83.69 and a beta of 0.80. agilon health has a 12 month low of $14.82 and a 12 month high of $28.36. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.48 and a quick ratio of 2.48.
agilon health (NYSE:AGL – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $694.86 million for the quarter, compared to the consensus estimate of $651.24 million. agilon health had a negative return on equity of 9.31% and a negative net margin of 4.30%. As a group, research analysts predict that agilon health will post -0.21 earnings per share for the current fiscal year.
agilon health Company Profile
(Get Rating)
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries.
Featured Articles
- Get a free copy of the StockNews.com research report on agilon health (AGL)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.